Brady, whose post-football career has leaned heavily into health and wellness initiatives, is taking on a new C-suite role at eMed
Tom Brady’s latest move puts him inside telehealth, as the NFL legend takes on the role of chief wellness officer at digital health startup eMed.
The platform, which offers consumers access to weight-loss medications, includes at-home blood testing at onboarding, six months and 12 months, with results reviewed by medical providers to monitor progress. Members receive a side-effect care kit with over-the-counter remedies, along with screening and support to help manage common symptoms. There are also monthly clinical consultations and required check-ins.
A corporate offering is available to employers, providing eligible employees with access to GLP-1 medications and continuous clinical oversight.
“High-quality medical care should be accessible and delivered responsibly with decisions grounded in medical evidence and individual needs,” Brady said. “At eMed, the focus is improving population health at scale by delivering best-in-class GLP-1 care to workforce populations. These medications can be truly game-changing but only when paired with the right clinical guidance and ongoing support to protect long-term health.”
Before taking on his latest role at eMed, Brady had already built a sprawling footprint in the fitness and longevity economy. He co-founded TB12, a performance and recovery brand, co-founded Autograph, the fan platform that merged with personal training app Future last year and teamed with Gopuff to launch Goat Gummies, a better-for-you vegan snack. More recently, he was named chief innovation officer at Aescape, an AI-powered robotic massage company.
“GLP-1s are triggering a generational shift in healthcare and there’s no turning back,” eMed CEO Linda Yaccarino said. “Their adoption is one of the most urgent challenges employers face today, and the need for smarter, more disciplined care around these medications has never been greater. With Tom, we are accelerating our mission to offer a differentiated solution for the future of workplace health.”
The move coincides with a pivotal moment for GLP-1s: expanded access through oral formulations and growing evidence that weight often returns quickly when patients stop taking the drugs, highlighting the need for comprehensive support.
